Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) and NextCure (NASDAQ:NXTC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation. Profitability This table compares Mirum Pharmaceuticals and NextCure’s net margins, […]
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 545,100 shares, a drop of 27.2% from the March 15th total of 748,800 shares. Approximately 3.2% of the company’s shares are sold short. Based […]
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 748,800 shares, a growth of 55.7% from the February 28th total of 480,900 shares. Based on an average daily volume of 176,000 shares, the short-interest ratio is […]
Wall Street analysts forecast that Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) will report ($1.30) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for Mirum Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.47) and the highest is ($1.03). Mirum Pharmaceuticals posted earnings of ($1.68) per share in the […]
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) have been assigned an average recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong […]